{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:22:39Z","timestamp":1792232559357,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.euros.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T22:17:49Z","timestamp":1738016269000},"page":"31-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Incidence, Management, and Prevention of Gynecomastia and Breast Pain in Patients with Prostate Cancer Undergoing Antiandrogen Therapy: A Systematic Review and Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"73","author":[{"given":"Ichiro","family":"Tsuboi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoo","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2025.01.001_b0005","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.01.001_b0010","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.euo.2024.01.009","article-title":"A Phase 2 randomized open-label study of oral darolutamide monotherapy versus androgen deprivation therapy in men with hormone-sensitive prostate cancer (EORTC-GUCG 1532)","volume":"7","author":"Tombal","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2025.01.001_b0015","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1200\/JCO.22.01662","article-title":"Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: the SALV-ENZA trial","volume":"41","author":"Tran","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.01.001_b0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2025.01.001_b0025","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.01.001_b0030","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.01.001_b0035","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamaoncol.2022.1641","article-title":"Enzalutamide monotherapy vs active surveillance in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT randomized clinical trial","volume":"8","author":"Shore","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euros.2025.01.001_b0040","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00066-020-01598-9","article-title":"Treatment strategies to prevent and reduce gynecomastia and\/or breast pain caused by antiandrogen therapy for prostate cancer: statement from the DEGRO working group prostate cancer","volume":"196","author":"Ghadjar","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.euros.2025.01.001_b0045","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","article-title":"Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study","volume":"15","author":"Tombal","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2025.01.001_b0050","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1056\/NEJMcp070677","article-title":"Clinical practice. Gynecomastia","volume":"357","author":"Braunstein","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.01.001_b0055","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clgc.2012.03.002","article-title":"A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia","volume":"10","author":"Serretta","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euros.2025.01.001_b0060","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.juro.2010.03.137","article-title":"Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and\/or breast pain?","volume":"184","author":"Ozen","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2025.01.001_b0065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eururo.2009.05.019","article-title":"An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients","volume":"57","author":"Bedognetti","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.01.001_b0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.euros.2025.01.001_b0075","unstructured":"Rohatgi, A. (September, 2022). \"WebPlotDigitizer.\" 4.6. from https:\/\/automeris.io\/WebPlotDigitizer."},{"key":"10.1016\/j.euros.2025.01.001_b0080","first-page":"61","article-title":"Statistical data extraction and validation from graph for data integration and meta-analysis","volume":"6","author":"Shim","year":"2021","journal-title":"Korea J Big Data"},{"key":"10.1016\/j.euros.2025.01.001_b0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.euros.2025.01.001_b0090","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.eururo.2018.12.014","article-title":"Guidelines for reporting of statistics for clinical research in urology","volume":"75","author":"Assel","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.01.001_b0095","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5454727","article-title":"Randomized, open-label phase 2 study of apalutamide plus androgen deprivation therapy versus apalutamide monotherapy versus androgen deprivation monotherapy in patients with biochemically recurrent prostate cancer","volume":"2022","author":"Aggarwal","year":"2022","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.euros.2025.01.001_b0100","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2021.08.032","article-title":"A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)","volume":"158","author":"Maluf","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euros.2025.01.001_b0105","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s10147-019-01554-3","article-title":"Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study","volume":"25","author":"Iguchi","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.euros.2025.01.001_b0110","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2007.01.031","article-title":"Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study","volume":"52","author":"Fradet","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.01.001_b0115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.pcan.4500782","article-title":"Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole","volume":"8","author":"Saltzstein","year":"2005","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euros.2025.01.001_b0120","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(05)70103-0","article-title":"Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial","volume":"6","author":"Perdon\u00e0","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2025.01.001_b0125","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.2005.12.013","article-title":"Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer","volume":"23","author":"Boccardo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.01.001_b0130","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijrobp.2004.03.022","article-title":"Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia","volume":"60","author":"Tyrrell","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euros.2025.01.001_b0135","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0090-4295(02)02107-6","article-title":"Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7\/SFUO-3","volume":"61","author":"Widmark","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.euros.2025.01.001_b0140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.01.001_b0145","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2025.01.001_b0150","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.01.001_b0155","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1464-410X.2005.06051.x","article-title":"Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer","volume":"97","author":"McLeod","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2025.01.001_b0160","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S1470-2045(05)70464-2","article-title":"Management of gynaecomastia in patients with prostate cancer: a systematic review","volume":"6","author":"Di Lorenzo","year":"2005","journal-title":"Lancet Oncol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325000114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325000114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T20:24:04Z","timestamp":1740947044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168325000114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":32,"alternative-id":["S2666168325000114"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2025.01.001","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence, Management, and Prevention of Gynecomastia and Breast Pain in Patients with Prostate Cancer Undergoing Antiandrogen Therapy: A Systematic Review and Meta-analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}